

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

HOP-62

RRID:CVCL_1285

Type: Cell Line

Proper Citation

RRID:CVCL_1285

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1285

Proper Citation: RRID:CVCL_1285

Description: Cell line HOP-62 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:2041050](#), [PMID:2388294](#), [PMID:2536293](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:12068308](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22628656](#), [PMID:22961666](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HOP-62

Synonyms: HOP 62, Hop 62, HOP.62, HOP62, Hop62, Hopkins-62

Cross References: BTO:BTO_0004080, CLO:CLO_0037016, EFO:EFO_0006439, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770,

ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:418, BioSample:SAMN03471402, BioSample:SAMN10989587, cancercellines:CVCL_1285, Cell_Model_Passport:SIDM00133, ChEMBL-Cells:ChEMBL3307671, ChEMBL-Targets:ChEMBL614643, Cosmic:875855, Cosmic:905972, Cosmic:974289, Cosmic:1092603, Cosmic:1146945, Cosmic:1175861, Cosmic:1305344, Cosmic:1995442, Cosmic:1998445, Cosmic-CLP:905972, DepMap:ACH-000861, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905972, GEO:GSM2105, GEO:GSM50211, GEO:GSM50274, GEO:GSM206507, GEO:GSM274784, GEO:GSM274816, GEO:GSM434275, GEO:GSM743450, GEO:GSM750804, GEO:GSM794404, GEO:GSM799338, GEO:GSM799401, GEO:GSM846357, GEO:GSM1153408, GEO:GSM1178204, GEO:GSM1178205, GEO:GSM1178206, GEO:GSM1181256, GEO:GSM1181314, GEO:GSM1374542, GEO:GSM2124640, IARC_TP53:21113, IGRhCellID:HOP-62_02GEO, LiGeA:CCLE_548, LINCS_LDP:LCL-1666, NCI-DTP:HOP-62, PharmacDB:HOP62_561_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1285, PubChem_Cell_line:CVCL_1285, SKY/M-FISH/CGH:2896, Wikidata:Q54890155

ID: CVCL_1285

Record Creation Time: 20220427T220439+0000

Record Last Update: 20260829T233912+0000

Ratings and Alerts

No rating or validation information has been found for HOP-62.

No alerts have been found for HOP-62.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Criscuolo D, et al. (2026) KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion. Apoptosis : an international journal on programmed cell death, 31(8).

Davoudi Z, et al. (2025) RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types. Cancer research communications, 5(10), 1779.

Delafiori J, et al. (2025) HT SpaceM: A high-throughput and reproducible method for small-molecule single-cell metabolomics. Cell.

Bagnyukova T, et al. (2024) Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers. *Cancer research communications*, 4(5), 1227.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Kleszcz R, et al. (2023) Tannins in cancer prevention and therapy. *British journal of pharmacology*.

Tammaccaro SL, et al. (2023) TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC. *Pharmaceuticals (Basel, Switzerland)*, 16(4).

Sanidas I, et al. (2022) Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression. *Molecular cell*, 82(18), 3333.

Ma YC, et al. (2021) Urinary malate dehydrogenase 2 is a new biomarker for early detection of non-small-cell lung cancer. *Cancer science*, 112(6), 2349.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. *Cell chemical biology*, 27(1), 105.

Shirole NH, et al. (2016) TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions. *eLife*, 5.